Zacks: Analysts Expect Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Will Post Quarterly Sales of $300,000.00

Wall Street brokerages predict that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will report sales of $300,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Crinetics Pharmaceuticals’ earnings. The highest sales estimate is $550,000.00 and the lowest is $100,000.00. Crinetics Pharmaceuticals posted sales of $780,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 61.5%. The company is scheduled to report its next earnings results on Wednesday, March 11th.

According to Zacks, analysts expect that Crinetics Pharmaceuticals will report full-year sales of $1.06 million for the current fiscal year, with estimates ranging from $870,000.00 to $1.47 million. For the next financial year, analysts anticipate that the firm will post sales of $0.00. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.03). Crinetics Pharmaceuticals had a negative return on equity of 29.27% and a negative net margin of 1,303.31%. The business had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.33 million.

CRNX has been the topic of several research reports. Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. ValuEngine upgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd.

Crinetics Pharmaceuticals stock traded up $0.19 during midday trading on Tuesday, hitting $18.56. The company’s stock had a trading volume of 25,900 shares, compared to its average volume of 63,139. The company has a quick ratio of 19.07, a current ratio of 19.07 and a debt-to-equity ratio of 0.04. The stock’s 50-day moving average price is $17.11 and its 200-day moving average price is $20.83. Crinetics Pharmaceuticals has a 12 month low of $14.33 and a 12 month high of $36.95. The company has a market capitalization of $457.62 million, a PE ratio of -8.32 and a beta of 0.88.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC raised its holdings in Crinetics Pharmaceuticals by 6.5% during the 2nd quarter. Orbimed Advisors LLC now owns 2,039,282 shares of the company’s stock worth $50,982,000 after buying an additional 125,000 shares during the period. BlackRock Inc. raised its holdings in Crinetics Pharmaceuticals by 19.9% during the 2nd quarter. BlackRock Inc. now owns 932,424 shares of the company’s stock worth $23,312,000 after buying an additional 154,450 shares during the period. Vanguard Group Inc. raised its holdings in Crinetics Pharmaceuticals by 11.6% during the 2nd quarter. Vanguard Group Inc. now owns 504,539 shares of the company’s stock worth $12,614,000 after buying an additional 52,327 shares during the period. Janus Henderson Group PLC raised its holdings in Crinetics Pharmaceuticals by 2.3% during the 2nd quarter. Janus Henderson Group PLC now owns 499,542 shares of the company’s stock worth $12,489,000 after buying an additional 11,175 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Crinetics Pharmaceuticals by 0.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 487,916 shares of the company’s stock worth $12,198,000 after buying an additional 1,786 shares during the period. Hedge funds and other institutional investors own 78.20% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Read More: Why do companies issue monthly dividends?

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.